Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 201, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2020.112527
Keywords
Remdesivir (GS-5734); RdRP inhibitor; Coronavirus; COVID-19; Antiviral
Categories
Funding
- National Natural Science Foundation of China [81602967, 81803784]
- China Postdoctoral Science Foundation [2016M592898XB, 2019M663921XB]
- Basic Research Program of Natural Science of Shaanxi Province [2019JQ-779, 2020CGXNG-044, 19JC006]
- Basic Research Plan of the Education Department of Shaanxi Province [19JC006]
- College Students' Innovative Entrepreneurial Training Program [201510708172, 201610708019, 2019107080827]
Ask authors/readers for more resources
Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed. (C) 2020 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
